WO2010048347A3 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and compositions for diagnosis and prognosis of renal injury and renal failure Download PDF

Info

Publication number
WO2010048347A3
WO2010048347A3 PCT/US2009/061562 US2009061562W WO2010048347A3 WO 2010048347 A3 WO2010048347 A3 WO 2010048347A3 US 2009061562 W US2009061562 W US 2009061562W WO 2010048347 A3 WO2010048347 A3 WO 2010048347A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble
renal
prognosis
diagnosis
compositions
Prior art date
Application number
PCT/US2009/061562
Other languages
French (fr)
Other versions
WO2010048347A2 (en
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
Original Assignee
Astute Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical, Inc. filed Critical Astute Medical, Inc.
Priority to CA2740923A priority Critical patent/CA2740923A1/en
Priority to NZ592365A priority patent/NZ592365A/en
Priority to CN200980149636.XA priority patent/CN102246038B/en
Priority to JP2011532355A priority patent/JP2012506538A/en
Priority to US13/125,454 priority patent/US20110207161A1/en
Priority to EP09822670A priority patent/EP2347260A4/en
Priority to AU2009308375A priority patent/AU2009308375B2/en
Publication of WO2010048347A2 publication Critical patent/WO2010048347A2/en
Publication of WO2010048347A3 publication Critical patent/WO2010048347A3/en
Priority to HK12100121.8A priority patent/HK1159754A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C-X-C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin- 1, C-C motif chemokine 22, C-C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.
PCT/US2009/061562 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure WO2010048347A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2740923A CA2740923A1 (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592365A NZ592365A (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN200980149636.XA CN102246038B (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2011532355A JP2012506538A (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US13/125,454 US20110207161A1 (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP09822670A EP2347260A4 (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009308375A AU2009308375B2 (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK12100121.8A HK1159754A1 (en) 2008-10-21 2012-01-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
US10729308P 2008-10-21 2008-10-21
US10730708P 2008-10-21 2008-10-21
US10728708P 2008-10-21 2008-10-21
US61/107,293 2008-10-21
US61/107,287 2008-10-21
US61/107,307 2008-10-21
US11309308P 2008-11-10 2008-11-10
US11305908P 2008-11-10 2008-11-10
US11306908P 2008-11-10 2008-11-10
US11303908P 2008-11-10 2008-11-10
US11307808P 2008-11-10 2008-11-10
US11303408P 2008-11-10 2008-11-10
US61/113,093 2008-11-10
US61/113,078 2008-11-10
US61/113,034 2008-11-10
US61/113,039 2008-11-10
US61/113,059 2008-11-10
US61/113,069 2008-11-10
US11502808P 2008-11-14 2008-11-14
US11502608P 2008-11-14 2008-11-14
US61/115,028 2008-11-14
US61/115,026 2008-11-14
US11504308P 2008-11-15 2008-11-15
US11504608P 2008-11-15 2008-11-15
US11505008P 2008-11-15 2008-11-15
US61/115,043 2008-11-15
US61/115,050 2008-11-15
US61/115,046 2008-11-15
US11713808P 2008-11-22 2008-11-22
US11713608P 2008-11-22 2008-11-22
US11714308P 2008-11-22 2008-11-22
US61/117,143 2008-11-22
US61/117,136 2008-11-22
US61/117,138 2008-11-22

Publications (2)

Publication Number Publication Date
WO2010048347A2 WO2010048347A2 (en) 2010-04-29
WO2010048347A3 true WO2010048347A3 (en) 2010-06-17

Family

ID=42119969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061562 WO2010048347A2 (en) 2008-10-21 2009-10-21 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Country Status (9)

Country Link
US (1) US20110207161A1 (en)
EP (2) EP2767833A3 (en)
JP (3) JP2012506538A (en)
CN (3) CN104076152B (en)
AU (1) AU2009308375B2 (en)
CA (1) CA2740923A1 (en)
HK (3) HK1159754A1 (en)
NZ (2) NZ592365A (en)
WO (1) WO2010048347A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (en) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Methods of detecting signatures of disease or conditions in bodily fluids.
EP2324355B1 (en) 2008-08-28 2014-01-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102187219B (en) * 2008-08-29 2015-08-05 阿斯图特医药公司 For the method and composition of diagnosis and prognosis injury of kidney and kidney failure
CN102246035B (en) 2008-10-21 2014-10-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010054389A1 (en) 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2811036A3 (en) * 2008-11-22 2015-02-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120061863A (en) 2009-08-07 2012-06-13 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628085A (en) 2009-11-07 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120123056A (en) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX366653B (en) 2010-02-05 2019-07-17 Astute Medical Inc METHODS and COMPOSITIONS FOR DIAGNOSIS and PROGNOSIS OF RENAL INJURY and RENAL FAILURE.
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011106746A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20130041961A (en) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods for detecting signatures of disease or conditions in bodily fluids
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
US20130266940A1 (en) 2010-07-23 2013-10-10 President And Fellows Of Harvard College Methods of Detecting Kidney-Associated Diseases or Conditions
BR112013001752A2 (en) 2010-07-23 2016-05-31 Harvard College method of detecting disease or condition using phagocytic cells
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US20130330752A1 (en) 2011-01-29 2013-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2933570T3 (en) 2011-12-08 2023-02-10 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of kidney injury and kidney failure
CN107976547B (en) 2013-01-17 2020-08-25 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
CN104569417B (en) * 2013-10-12 2016-06-01 广州瑞博奥生物科技有限公司 A kind of antibody chip test kit for early diagnosis acute injury of kidney
EP4075139A1 (en) 2014-09-11 2022-10-19 Harry Stylli Methods of detecting prostate cancer
CN110702921B (en) 2014-10-20 2024-02-06 阿斯图特医药公司 Methods and compositions for diagnosing and prognosing kidney injury and renal failure
US20170131291A1 (en) * 2015-10-05 2017-05-11 Seinda Biomedical Corporation Methods and devices for diagnosing ocular surface inflammation and dry eye disease
CL2015003047A1 (en) 2015-10-15 2016-06-17 Univ Chile Ex vivo method to detect acute renal injury early in critically ill patients, which includes mediciom in a sample of three proteins as biomarkers, fibroblastic growth factor 23, klotho and erythropoietin
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US20200174014A1 (en) 2016-12-19 2020-06-04 Osaka University METHOD FOR IN VITRO EARLY DIAGNOSIS OF ANTIBODY MEDIATED REJECTION AFTER ORGAN TRANSPLANTATION USING IgM-TYPE MEMORY B CELL DIFFERENTIATION CULTURE SYSTEM
AU2018207151B2 (en) 2017-01-12 2024-02-29 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2018231986A1 (en) * 2017-06-13 2018-12-20 Rogers Wade T Compositions and methods for predicting post-surgical cardiovascular events
WO2020122998A1 (en) * 2018-12-12 2020-06-18 Medibeacon Inc. Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
JP2022049718A (en) * 2019-02-05 2022-03-30 アステラス製薬株式会社 Treatment of retinal degenerative disease by introduction of cx3cl1 gene using adeno-associated virus
WO2022109067A1 (en) 2020-11-18 2022-05-27 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060088823A1 (en) * 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20060204951A1 (en) * 2004-04-26 2006-09-14 Judah Folkman Platelet biomarkers for the detection of disease
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
ATE195808T1 (en) 1991-04-12 2000-09-15 Biosite Diagnostics Inc NEW CONJUGATES AND TEST METHODS FOR THE SIMULTANEOUS DETERMINATION OF MULTIPLE LIGANDS
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
TR199802421T2 (en) * 1996-05-24 1999-02-22 Biogen , Inc. Substances that regulate tissue regeneration.
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20060223077A1 (en) * 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
AU1674400A (en) * 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment
AU2002216273A1 (en) * 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
HUP0400659A3 (en) * 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
EP2299274A1 (en) * 2002-03-07 2011-03-23 Medical Research Council SCD fingerprints
EP1532268A4 (en) * 2002-03-21 2006-07-05 Yissum Res Dev Co Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138229B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
AU2003298689A1 (en) * 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20060063156A1 (en) * 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
CN1791797A (en) * 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
US7354584B2 (en) * 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US7560244B2 (en) * 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
DE10332101B4 (en) * 2003-07-15 2016-02-04 Kennametal Inc. Cutting tool and method for its production
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
CA2560200A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US20080038192A1 (en) * 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
US7141382B1 (en) * 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
CN100381460C (en) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 HER-2 analogue antigen epitope and peptide containing said epitope
DK1841316T3 (en) * 2005-01-10 2011-08-08 Univ Rosalind Franklin Medicine & Science CCN3 protein for use in the treatment and diagnosis of kidney disease
EP1846576A4 (en) * 2005-02-01 2009-01-07 Us Gov Health & Human Serv Biomarkers for tissue status
WO2006099421A2 (en) * 2005-03-14 2006-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
KR101363032B1 (en) * 2005-04-18 2014-02-13 미토믹스 인크. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7833732B2 (en) * 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
US7759077B2 (en) * 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) * 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
WO2007070870A1 (en) * 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) * 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en) * 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) * 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) * 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
WO2008005375A2 (en) * 2006-06-30 2008-01-10 Merck & Co., Inc. Kidney toxicity biomarkers
WO2008009132A1 (en) * 2006-07-21 2008-01-24 The Governors Of The University Of Alberta Tissue rejection
GB0617429D0 (en) * 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) * 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
WO2008073899A2 (en) * 2006-12-08 2008-06-19 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CA2681792A1 (en) * 2007-03-26 2008-10-02 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US8080394B2 (en) * 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
WO2008150488A1 (en) * 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2009039421A1 (en) * 2007-09-20 2009-03-26 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US8003333B2 (en) * 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
US20090298106A1 (en) * 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en) * 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US7998744B2 (en) * 2008-07-28 2011-08-16 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
WO2010022210A2 (en) * 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
EP2324355B1 (en) * 2008-08-28 2014-01-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102187219B (en) * 2008-08-29 2015-08-05 阿斯图特医药公司 For the method and composition of diagnosis and prognosis injury of kidney and kidney failure
US8501489B2 (en) * 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
CN102246035B (en) * 2008-10-21 2014-10-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011017682A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Devices for detecting renal disorders
EP2480882A4 (en) * 2009-09-21 2013-07-10 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130035290A1 (en) * 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088823A1 (en) * 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US20060204951A1 (en) * 2004-04-26 2006-09-14 Judah Folkman Platelet biomarkers for the detection of disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUGO ET AL.: "Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat", KIDNEY INTERNATIONAL, vol. 53, 1998, pages 302 - 311, XP008146862 *
SCHIFFER ET AL.: "Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis", JOURNAL OF IMMUNOLOGY, vol. 180, 1 February 2008 (2008-02-01), pages 1938 - 1947, XP008147300 *
See also references of EP2347260A4 *

Also Published As

Publication number Publication date
EP2767833A2 (en) 2014-08-20
AU2009308375B2 (en) 2015-06-25
CN102246038A (en) 2011-11-16
CN104020284A (en) 2014-09-03
CA2740923A1 (en) 2010-04-29
CN104076152A (en) 2014-10-01
WO2010048347A2 (en) 2010-04-29
EP2767833A3 (en) 2014-12-17
US20110207161A1 (en) 2011-08-25
JP5955879B2 (en) 2016-07-20
HK1198342A1 (en) 2015-04-02
CN102246038B (en) 2014-06-18
HK1159754A1 (en) 2012-08-03
HK1199929A1 (en) 2015-07-24
JP2016186494A (en) 2016-10-27
NZ619918A (en) 2015-04-24
JP2014139578A (en) 2014-07-31
JP2012506538A (en) 2012-03-15
CN104020284B (en) 2016-08-24
EP2347260A2 (en) 2011-07-27
NZ592365A (en) 2014-08-29
CN104076152B (en) 2017-04-19
EP2347260A4 (en) 2012-09-26
AU2009308375A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2010048347A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
EP2811036A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX341191B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX336280B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
WO2006124526A3 (en) Method for assessing the effectiveness of a treatment regimen by determining zonulin
EP2585827A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE602007011566D1 (en) Ankheit
WO2007030928A3 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
WO2007106224A3 (en) Method of detecting or diagnosing of a neurodegenerative disease or condition
EA201290192A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
EP2585826A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016064877A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012094658A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012003168A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure.
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Shobha et al. Histopathology of lupus nephritis: A single-center, cross-sectional study from Karnataka, India

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980149636.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822670

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011532355

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2740923

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 592365

Country of ref document: NZ

Ref document number: 2009308375

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13125454

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 967/MUMNP/2011

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2009822670

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009822670

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009308375

Country of ref document: AU

Date of ref document: 20091021

Kind code of ref document: A